Who makes LEXETTE 0.05% Topical Foam?

LEXETTE 0.05% Topical Foam is developed by Skin Sciences, PLLC.

What development phase is LEXETTE 0.05% Topical Foam in?

LEXETTE 0.05% Topical Foam is FDA-approved (marketed).

Last reviewed 2026-05-15 · How we verify

LEXETTE 0.05% Topical Foam

Skin Sciences, PLLC · FDA-approved active Small molecule Quality 2/100

At a glance

Generic name	LEXETTE 0.05% Topical Foam
Also known as	Halobetasol Propionate Topical Foam
Sponsor	Skin Sciences, PLLC
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Efficacy and Safety of Sorilux in Maintenance Treatment of Moderate Type Plaque Psoriasis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LEXETTE 0.05% Topical Foam CI brief — competitive landscape report
LEXETTE 0.05% Topical Foam updates RSS · CI watch RSS
Skin Sciences, PLLC portfolio CI